Updated European Consensus Statement on diagnosis and treatment of adult ADHD
書誌事項
- 公開日
- 2018-11-16
- 権利情報
-
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- https://www.elsevier.com/tdm/userlicense/1.0/
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1016/j.eurpsy.2018.11.001
- 10.17863/cam.56499
- 公開者
- Cambridge University Press (CUP)
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:sec id="S092493380000910X_abst0005" sec-type="other"><jats:title/><jats:p>Background Attention-deficit/hyperactivity disorder (ADHD) is among the most common psychiatric disorders of childhood that often persists into adulthood and old age. Yet ADHD is currently underdiagnosed and undertreated in many European countries, leading to chronicity of symptoms and impairment, due to lack of, or ineffective treatment, and higher costs of illness.</jats:p><jats:p>Methods The European Network Adult ADHD and the Section for Neurodevelopmental Disorders Across the Lifespan (NDAL) of the European Psychiatric Association (EPA), aim to increase awareness and knowledge of adult ADHD in and outside Europe. This Updated European Consensus Statement aims to support clinicians with research evidence and clinical experience from 63 experts of European and other countries in which ADHD in adults is recognized and treated.</jats:p><jats:p>Results Besides reviewing the latest research on prevalence, persistence, genetics and neurobiology of ADHD, three major questions are addressed: (1) What is the clinical picture of ADHD in adults? (2) How should ADHD be properly diagnosed in adults? (3) How should adult ADHDbe effectively treated?</jats:p><jats:p>Conclusions ADHD often presents as a lifelong impairing condition. The stigma surrounding ADHD, mainly due to lack of knowledge, increases the suffering of patients. Education on the lifespan perspective, diagnostic assessment, and treatment of ADHD must increase for students of general and mental health, and for psychiatry professionals. Instruments for screening and diagnosis of ADHD in adults are available, as are effective evidence-based treatments for ADHD and its negative outcomes. More research is needed on gender differences, and in older adults with ADHD.</jats:p></jats:sec>
収録刊行物
-
- European Psychiatry
-
European Psychiatry 56 (1), 14-34, 2018-11-16
Cambridge University Press (CUP)
- Tweet
キーワード
- Male
- MENTAL-HEALTH-SERVICES
- 150
- Adult ADHD; Updated European Consensus Statement; Diagnosis; Treatment; European Network Adult ADHD; EPA
- SERIOUS CARDIOVASCULAR EVENTS
- MEDICATION-TREATED ADULTS
- GUANFACINE EXTENDED-RELEASE
- Health Services Accessibility
- Adult ADHD
- Diagnosis
- Prevalence
- Psychology
- COGNITIVE-BEHAVIORAL THERAPY
- 11 Medical and Health Sciences
- Psychiatry
- TREATMENT
- BORDERLINE PERSONALITY-DISORDER
- RANDOMIZED CONTROLLED-TRIAL
- ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER
- 17 Psychology and Cognitive Sciences
- Europe
- Practice Guidelines as Topic
- Mental health
- Female
- Life Sciences & Biomedicine
- Adult
- Consensus
- 610
- DIAGNOSIS
- Psykiatri
- Neurology and psychiatry
- Humans
- DEFICIT-HYPERACTIVITY-DISORDER
- Science & Technology
- 3202 Clinical sciences
- EPA
- 5203 Clinical and health psychology
- Treatment
- Psychotherapy
- 5202 Biological psychology
- Attention Deficit Disorder with Hyperactivity
- SUBSTANCE USE DISORDER
- Central Nervous System Stimulants
- Human medicine
- European Network Adult ADHD
- Updated European Consensus Statement
詳細情報 詳細情報について
-
- CRID
- 1360580237201534976
-
- ISSN
- 17783585
- 09249338
-
- PubMed
- 30453134
-
- データソース種別
-
- Crossref
- OpenAIRE

